|
[X]
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
|
|
|
For the fiscal year ended December 31, 2011
|
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
|
|
|
For the transition period from to
|
|
Delaware
|
|
39-0394230
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
P. O. Box 619100, Dallas, Texas
|
|
75261-9100
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Title of each class
|
|
Name of each exchange on which registered
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock—$1.25 Par Value
|
|
New York Stock Exchange
|
||||||||
|
Large accelerated filer
x
|
|
Accelerated filer
o
|
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
o
|
|
|
|
Page
|
|
Part I
|
|
|
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 1B.
|
||
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
|
|
|
|
Part II
|
|
|
|
Item 5.
|
||
|
Item 6.
|
||
|
Item 7.
|
||
|
Item 7A.
|
||
|
Item 8.
|
||
|
Item 9.
|
||
|
Item 9A.
|
||
|
Item 9B.
|
||
|
|
|
|
|
Part III
|
|
|
|
Item 10.
|
||
|
Item 11.
|
||
|
Item 12.
|
||
|
Item 13.
|
||
|
Item 14.
|
||
|
|
|
|
|
Part IV
|
|
|
|
Item 15.
|
||
|
|
|
|
|
•
|
Personal Care
brands offer parents a trusted partner in caring for their families and deliver confidence, protection and discretion to adults through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, Kotex, Lightdays, Depend, Poise and other brand names.
|
|
•
|
Consumer Tissue
offers a wide variety of innovative solutions and trusted brands that touch and improve people's lives every day. Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Hakle, Page and other brand names.
|
|
•
|
K-C Professional & Other
helps transform workplaces for employees and patrons, making them healthier, safer, and more productive, through a range of solutions and supporting products such as apparel, wipers, soaps, sanitizers, tissues, and towels. Key brands in this segment include Kleenex, Scott, WypAll, Kimtech, and Jackson
Safety.
|
|
•
|
Health Care
provides the essentials that help restore patients to better health and improve the quality of patients' lives. Through a portfolio of innovative medical device and infection prevention products, Health Care offers clinicians a range of solutions in pain management, respiratory and digestive health and medical supplies for the operating room. This business is a global leader in education to prevent healthcare-associated infections. Products are sold primarily under the Kimberly-Clark and ON-Q brand names.
|
|
|
2012
|
|
2013
|
||||
|
|
(Millions of dollars)
|
||||||
|
Facilities in U.S.
|
$
|
6
|
|
|
$
|
22
|
|
|
Facilities outside U.S.
|
23
|
|
|
19
|
|
||
|
Total
|
$
|
29
|
|
|
$
|
41
|
|
|
|
2012
|
|
2013
|
||||
|
|
(Millions of dollars)
|
||||||
|
Facilities in U.S.
|
$
|
58
|
|
|
$
|
78
|
|
|
Facilities outside U.S.
|
68
|
|
|
67
|
|
||
|
Total
|
$
|
126
|
|
|
$
|
145
|
|
|
•
|
consumer demand for our products, including shifting consumer purchasing patterns to lower-cost options such as private-label products, as well as declining birth rates in countries due to slow economic growth or other factors,
|
|
•
|
demand by businesses for our products, including the effects of increased unemployment and cost savings efforts of customers,
|
|
•
|
the social and political environment,
|
|
•
|
the product mix of our sales, and
|
|
•
|
our ability to collect accounts receivable on a timely basis from certain customers.
|
|
•
|
our principal executive offices, located in the Dallas, Texas metropolitan area;
|
|
•
|
five operating segment and geographic headquarters at two U.S. and three international locations; and
|
|
•
|
five administrative centers at two U.S. and three international locations.
|
|
Geographic Area
:
|
Number of
Facilities
|
|
|
United States (in 19 states)
|
25
|
|
|
Canada
|
1
|
|
|
Europe
|
18
|
|
|
Asia, Latin America and Other
|
62
|
|
|
Worldwide Total (in 39 countries)
|
106
|
|
|
Products Produced
:
|
Number of
Facilities
|
|
|
Tissue, including consumer tissue and K-C Professional & Other products
|
63
|
|
|
Personal Care
|
51
|
|
|
Health Care
|
14
|
|
|
ITEM 5.
|
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
|
|
|
Year Ended December 31
|
||||||||||||||||||
|
|
(In Millions, except per share amounts)
|
||||||||||||||||||
|
|
2011
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
||||||||||
|
Net Sales
|
$
|
20,846
|
|
|
$
|
19,746
|
|
|
$
|
19,115
|
|
|
$
|
19,415
|
|
|
$
|
18,266
|
|
|
Gross Profit
|
6,152
|
|
|
6,550
|
|
|
6,420
|
|
|
5,858
|
|
|
5,704
|
|
|||||
|
Operating Profit
|
2,442
|
|
|
2,773
|
|
|
2,825
|
|
|
2,547
|
|
|
2,616
|
|
|||||
|
Share of net income of equity companies
|
161
|
|
|
181
|
|
|
164
|
|
|
166
|
|
|
170
|
|
|||||
|
Net Income
|
1,684
|
|
|
1,943
|
|
|
1,994
|
|
|
1,829
|
|
|
1,951
|
|
|||||
|
Net income attributable to noncontrolling interests
|
(93
|
)
|
|
(100
|
)
|
|
(110
|
)
|
|
(139
|
)
|
|
(128
|
)
|
|||||
|
Net Income Attributable to Kimberly-Clark Corporation
|
1,591
|
|
|
1,843
|
|
|
1,884
|
|
|
1,690
|
|
|
1,823
|
|
|||||
|
Per Share Basis:
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Basic
|
4.02
|
|
|
4.47
|
|
|
4.53
|
|
|
4.04
|
|
|
4.11
|
|
|||||
|
Diluted
|
3.99
|
|
|
4.45
|
|
|
4.52
|
|
|
4.03
|
|
|
4.08
|
|
|||||
|
Cash Dividends Per Share
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Declared
|
2.80
|
|
|
2.64
|
|
|
2.40
|
|
|
2.32
|
|
|
2.12
|
|
|||||
|
Paid
|
2.76
|
|
|
2.58
|
|
|
2.38
|
|
|
2.27
|
|
|
2.08
|
|
|||||
|
Total Assets
|
19,373
|
|
|
19,864
|
|
|
19,209
|
|
|
18,089
|
|
|
18,440
|
|
|||||
|
Long-Term Debt
|
5,426
|
|
|
5,120
|
|
|
4,792
|
|
|
4,882
|
|
|
4,394
|
|
|||||
|
Total Stockholders’ Equity
|
5,529
|
|
|
6,202
|
|
|
5,690
|
|
|
4,261
|
|
|
5,687
|
|
|||||
|
ITEM 7.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
•
|
Overview of Business
|
|
•
|
Overview of
2011
Results
|
|
•
|
Results of Operations and Related Information
|
|
•
|
Liquidity and Capital Resources
|
|
•
|
Variable Interest Entities
|
|
•
|
Critical Accounting Policies and Use of Estimates
|
|
•
|
Legal Matters
|
|
•
|
New Accounting Standards
|
|
•
|
Business Outlook
|
|
•
|
Forward-Looking Statements
|
|
•
|
We plan to grow our strong positions in Personal Care by leveraging our brands and providing innovations.
|
|
•
|
For Consumer Tissue, we seek to bring differentiated, value-added innovations to grow and strengthen our brands while focusing on net realized revenue, improving mix and reducing costs.
|
|
•
|
We plan to continue to shift our mix to faster-growing, higher margin segments within KCP and Health Care, including safety and wiping in KCP and medical devices in Health Care.
|
|
•
|
We launched a number of new or improved products, including Huggies Little Movers Slip-On Diapers, Poise Hourglass Shape Pads, Kleenex Cool Touch Facial Tissue, U by Kotex Tweens and improved Cottenelle bathroom tissue. These innovations are the latest examples of our ability to translate consumer insights into solutions that generate growth.
|
|
•
|
Our innovations and supporting marketing programs helped improve our brands' market positions. In the U.S., we improved or maintained market share in the majority of our consumer categories. We also increased our market share in a number of businesses in KCI.
|
|
•
|
We executed our growth strategies in KCI. Net sales grew at a double-digit rate in 2011, including high single-digit growth before taking into account the impact of changes in foreign currency exchange rates. KCI accounted for about 36 percent of company sales in 2011, up 3 points from the previous year.
|
|
•
|
We took steps to offset significant cost inflation. We achieved higher overall net selling prices of 2 percent, we delivered approximately $265 million in ongoing cost savings, and we tightly controlled overhead spending. These actions helped offset cost inflation of $580 million.
|
|
•
|
As described in "Pulp and Tissues Restructuring" below, in January of 2011, we initiated a pulp and tissue restructuring to exit our remaining integrated pulp manufacturing operations and improve the underlying profitability and return on invested capital of our consumer tissue and KCP businesses. In January of 2012, we decided to streamline an additional facility in North America to further enhance the profitability of the consumer tissue business. Both restructuring actions are expected to be substantially completed by the end of 2012.
|
|
•
|
We repurchased $1.24 billion of Kimberly-Clark common stock in 2011, and expect to repurchase $900 million to $1.1 billion of our common stock in 2012, subject to market conditions. In addition, we raised our dividend in 2011 by 6 percent, the 39
th
consecutive annual increase in our dividend. Altogether, share repurchases and dividends in 2011 amounted to $2.3 billion.
|
|
•
|
Net sales increased 5.6 percent due to favorable currency effects, increases in net selling prices and increases in volume.
|
|
•
|
Operating profit decreased 11.9 percent and net income attributable to Kimberly-Clark Corporation and diluted earnings per share decreased 13.7 percent and 10.3 percent, respectively.
|
|
•
|
Results were negatively impacted by
$415 million
in pretax charges, $289 million after tax, for the pulp and tissue restructuring actions.
|
|
•
|
Cash provided by operations was $2.3 billion, a decrease of 16.6 percent compared to last year, driven primarily by higher defined benefit pension plan contributions in 2011.
|
|
|
Year Ended December 31
|
||||||||||
|
2011
|
|
2010
|
|
2009
|
|||||||
|
(Millions of dollars)
|
|||||||||||
|
Personal Care
|
$
|
9,128
|
|
|
$
|
8,670
|
|
|
$
|
8,365
|
|
|
Consumer Tissue
|
6,770
|
|
|
6,497
|
|
|
6,409
|
|
|||
|
K-C Professional & Other
|
3,294
|
|
|
3,110
|
|
|
3,007
|
|
|||
|
Health Care
|
1,606
|
|
|
1,460
|
|
|
1,371
|
|
|||
|
Corporate & Other
|
48
|
|
|
9
|
|
|
(37
|
)
|
|||
|
Consolidated
|
$
|
20,846
|
|
|
$
|
19,746
|
|
|
$
|
19,115
|
|
|
|
Year Ended December 31
|
||||||||||
|
2011
|
|
2010
|
|
2009
|
|||||||
|
(Millions of dollars)
|
|||||||||||
|
United States
|
$
|
10,463
|
|
|
$
|
10,480
|
|
|
$
|
10,146
|
|
|
Canada
|
726
|
|
|
684
|
|
|
596
|
|
|||
|
Intergeographic sales
|
(443
|
)
|
|
(445
|
)
|
|
(322
|
)
|
|||
|
Total North America
|
10,746
|
|
|
10,719
|
|
|
10,420
|
|
|||
|
Europe
|
3,401
|
|
|
3,179
|
|
|
3,220
|
|
|||
|
Asia, Latin America and other
|
7,467
|
|
|
6,561
|
|
|
6,124
|
|
|||
|
Intergeographic sales
|
(768
|
)
|
|
(713
|
)
|
|
(649
|
)
|
|||
|
Consolidated
|
$
|
20,846
|
|
|
$
|
19,746
|
|
|
$
|
19,115
|
|
|
|
Percent Change in Net Sales Versus Prior Year
|
||||||||
|
Total
Change |
|
Changes Due To
|
|||||||
|
|
Volume
|
|
Net
Price |
|
Mix/
Other
|
|
Currency
|
||
|
Consolidated
|
5.6
|
|
1
|
|
2
|
|
—
|
|
3
|
|
Personal Care
|
5.3
|
|
2
|
|
1
|
|
(1)
|
|
3
|
|
Consumer Tissue
|
4.2
|
|
(2)
|
|
3
|
|
—
|
|
3
|
|
K-C Professional & Other
|
5.9
|
|
2
|
|
2
|
|
(1)
|
|
3
|
|
Health Care
|
10.0
|
|
8
|
|
—
|
|
—
|
|
2
|
|
•
|
Personal care net sales in North America decreased about 2 percent due to lower net selling prices and unfavorable product mix of 2 percent and 1 percent, respectively, partially offset by favorable currency effects. Volumes were essentially flat as improvements in baby wipes, adult incontinence products and feminine care, including benefits from product innovation in the Poise, Depend and U by Kotex brands, were mostly offset by lower sales of Huggies diapers and Pull-Ups training pants.
|
|
•
|
Consumer tissue net sales in North America increased 2 percent due to higher net selling prices of 2 percent, partially offset by a sales volume decline of about 1 percent. Sales volumes were up high single-digits in paper towels but were more than offset by low single-digits decreases in both bath and facial tissue.
|
|
•
|
KCP's net sales in North America increased 3 percent due to higher net selling prices of 2 percent and an increase in sales volumes of 1 percent driven by the safety and wiper categories, while washroom product volumes declined in a continued challenging economic environment. In Europe, sales of KCP products increased 7 percent due to favorable currency effects of 6 percent and increased sales volumes of about 2 percent. Net sales in KCI of KCP products increased 14 percent due to favorable currency effects of 6 percent, higher sales volumes of 5 percent and higher net selling prices of 3 percent.
|
|
•
|
Higher sales volumes for health care products were driven by increases in exam gloves and medical devices.
|
|
|
Percent Change in Net Sales Versus Prior Year
|
||||||||
|
Total
Change |
|
Changes Due To
|
|||||||
|
Volume
Growth |
|
Net
Price |
|
Mix/
Other
|
|
Currency
|
|||
|
Consolidated
|
3.3
|
|
1
|
|
1
|
|
—
|
|
1
|
|
Personal Care
|
3.6
|
|
3
|
|
—
|
|
—
|
|
1
|
|
Consumer Tissue
|
1.4
|
|
(2)
|
|
2
|
|
—
|
|
1
|
|
K-C Professional & Other
|
3.4
|
|
1
|
|
2
|
|
—
|
|
—
|
|
Health Care
|
6.5
|
|
7
|
|
(2)
|
|
1
|
|
—
|
|
•
|
Personal care net sales in North America increased about 4 percent due to an increase in sales volumes and net selling prices of 3 percent and 1 percent, respectively. The sales volume increases resulted from higher sales of Pull-Ups training pants and baby wipes, feminine care and adult incontinence products, including benefits from innovation in the U by Kotex, Poise and Depend brands, partially offset by lower sales of Huggies diapers.
|
|
•
|
Consumer tissue net sales in North America decreased 1 percent as an increase in net selling prices of 2 percent and
|
|
•
|
KCP's net sales in North America increased 3 percent due to higher net selling prices of about 2 percent and favorable currency effects of 1 percent. Volume comparisons benefited from the Jackson Products, Inc. acquisition in 2009 and growth in the wiper and safety categories, while washroom product volumes declined in a continued challenging economic environment. In Europe, sales of KCP products decreased 1 percent, as an increase in sales volumes of 3 percent was more than offset by unfavorable currency effects of 3 percent and lower net selling prices of 1 percent.
|
|
•
|
The increased sales volumes for health care products were primarily due to a 9 percent benefit from the acquisition of I-Flow Corporation ("I-Flow") in late November 2009, as well as volume increases in other medical devices, which were more than offset by declines in supplies, including the impact from increased face mask demand in 2009 related to the H1N1 influenza virus.
|
|
|
Year Ended December 31
|
||||||||||
|
|
2011
|
|
2010
|
|
2009
|
||||||
|
|
(Millions of dollars)
|
||||||||||
|
Personal Care
|
$
|
1,526
|
|
|
$
|
1,764
|
|
|
$
|
1,739
|
|
|
Consumer Tissue
|
775
|
|
|
660
|
|
|
736
|
|
|||
|
K-C Professional & Other
|
487
|
|
|
468
|
|
|
464
|
|
|||
|
Health Care
|
219
|
|
|
174
|
|
|
244
|
|
|||
|
Other (income) and expense, net
|
(51
|
)
|
|
104
|
|
|
97
|
|
|||
|
Corporate & Other
|
(616
|
)
|
|
(189
|
)
|
|
(261
|
)
|
|||
|
Consolidated
|
$
|
2,442
|
|
|
$
|
2,773
|
|
|
$
|
2,825
|
|
|
|
Year Ended December 31
|
||||||||||
|
|
2011
|
|
2010
|
|
2009
|
||||||
|
|
(Millions of dollars)
|
||||||||||
|
United States
|
$
|
1,754
|
|
|
$
|
1,901
|
|
|
$
|
2,059
|
|
|
Canada
|
161
|
|
|
125
|
|
|
113
|
|
|||
|
Europe
|
170
|
|
|
222
|
|
|
171
|
|
|||
|
Asia, Latin America and other
|
922
|
|
|
818
|
|
|
840
|
|
|||
|
Other (income) and expense, net
|
(51
|
)
|
|
104
|
|
|
97
|
|
|||
|
Corporate & Other
|
(616
|
)
|
|
(189
|
)
|
|
(261
|
)
|
|||
|
Consolidated
|
$
|
2,442
|
|
|
$
|
2,773
|
|
|
$
|
2,825
|
|
|
|
Percentage Change in Operating Profit Versus Prior Year
|
||||||||||||
|
|
|
|
Change Due To
|
||||||||||
|
|
Total
Change |
|
Volume
|
|
Net
Price |
|
Input
Costs
(a)
|
|
Cost
Savings |
|
Currency
|
|
Other
(b)
|
|
Consolidated
|
(11.9)
|
|
3
|
|
13
|
|
(21)
|
|
10
|
|
5
|
|
(22)
|
|
Personal Care
|
(13.5)
|
|
3
|
|
6
|
|
(18)
|
|
5
|
|
2
|
|
(11)
|
|
Consumer Tissue
|
17.4
|
|
(4)
|
|
28
|
|
(19)
|
|
16
|
|
2
|
|
(6)
|
|
K-C Professional & Other
|
4.1
|
|
4
|
|
12
|
|
(18)
|
|
13
|
|
5
|
|
(12)
|
|
Health Care
|
25.9
|
|
24
|
|
2
|
|
(33)
|
|
11
|
|
3
|
|
19
|
|
(a)
|
Includes inflation in raw materials, energy and distribution costs.
|
|
(b)
|
Consolidated includes the effect of the 2011 pulp and tissue restructuring charges and a non-deductible business tax charge related to a law change in Colombia, as well as the impact of the 2010 charge related to the adoption of highly inflationary accounting in Venezuela.
|
|
•
|
Consolidated operating profit decreased $331 million compared to the prior year. The benefits of increases in net sales and cost savings of $265 million were more than offset by charges of
$415 million
related to the pulp and tissue restructuring, inflation in key cost inputs of $580 million and the negative effect of lower production volumes. Comparisons were also impacted by the effect of a $98 million charge related to the adoption of highly inflationary accounting in Venezuela in 2010.
|
|
•
|
Operating profit for the personal care segment decreased due to inflation in key cost inputs and the negative effect of lower production volumes, partially offset by increases in net sales and cost savings. In North America, operating profit decreased due to inflation in key cost inputs, lower net sales and the negative effects of lower production volumes, partially offset by lower marketing, research and general expenses. In Europe, operating profit decreased due to inflation in key cost inputs, partially offset by cost savings, higher net sales and lower marketing, research and general expenses. Operating profit in KCI increased due to higher net sales, cost savings and favorable currency effects, partially offset by inflation in key cost inputs and increases in marketing, research and general expenses.
|
|
•
|
Consumer tissue segment operating profit increased due to increases in net sales, cost savings and lower marketing, research and general expenses, partially offset by inflation in key cost inputs and the negative effect of lower production volumes. Operating profit in North America increased as higher net sales, cost savings and lower marketing, research and general expenses were partially offset by inflation in key cost inputs. In Europe, operating profit decreased as favorable currency effects, cost savings and lower general expenses were more than offset by inflation in key cost inputs. Operating profit in KCI increased as higher net sales and favorable currency effects were partially offset by the negative effect of production volumes and inflation in key cost inputs.
|
|
•
|
Operating profit for KCP & Other increased due to higher net sales, cost savings and favorable currency effects, partially offset by inflation in key cost inputs and increased marketing, research and general expenses.
|
|
•
|
Operating profit for the health care segment increased as higher net sales, cost savings and lower marketing, research and general expenses, primarily due to a lower level of litigation expenses, were partially offset by inflation in key cost inputs.
|
|
|
Percentage Change in Operating Profit Versus Prior Year
|
||||||||||||
|
|
|
|
Change Due To
|
||||||||||
|
|
Total
Change |
|
Volume
|
|
Net
Price |
|
Input
Costs (a) |
|
Cost
Savings |
|
Currency
|
|
Other
(b)
|
|
Consolidated
|
(1.8)
|
|
2
|
|
8
|
|
(28)
|
|
13
|
|
—
|
|
3
|
|
Personal Care
|
1.4
|
|
3
|
|
2
|
|
(16)
|
|
11
|
|
(3)
|
|
4
|
|
Consumer Tissue
|
(10.3)
|
|
(5)
|
|
21
|
|
(45)
|
|
13
|
|
(6)
|
|
12
|
|
K-C Professional & Other
|
0.9
|
|
(6)
|
|
14
|
|
(31)
|
|
10
|
|
(3)
|
|
17
|
|
Health Care
|
(28.7)
|
|
29
|
|
(9)
|
|
(19)
|
|
12
|
|
2
|
|
(44)
|
|
(a)
|
Includes inflation in raw materials, energy and distribution costs.
|
|
(b)
|
Includes the effect of the 2009 organization optimization initiative charges and related benefits. Consolidated also includes the effect of the charge related to the adoption of highly inflationary accounting in Venezuela in 2010.
|
|
•
|
Consolidated operating profit decreased $52 million or 1.8 percent compared to the prior year. The benefits of increases in net sales, cost savings of $370 million, and a decrease in pension expense of about $120 million, were more than offset by inflation in key cost inputs of about $790 million, and increased marketing, research and general expenses, which included higher strategic marketing spending of about $100 million, and increases related to I-Flow and to support future growth in KCI. Comparisons were also impacted by the effect of the organization optimization initiative charges of $128 million in 2009 and related benefits in 2010, and a $98 million charge related to the adoption of highly inflationary accounting in Venezuela. Operating profit as a percent of net sales decreased to 14.0 percent from 14.8 percent in 2009.
|
|
•
|
Operating profit for the personal care segment increased 1.4 percent as higher sales volumes, higher net selling prices, and cost savings were mostly offset by inflation in key cost inputs, increased marketing, research and general expenses and unfavorable currency effects. In North America, operating profit increased due to cost savings, higher net selling prices, increased sales volumes, and favorable currency effects, partially offset by inflation in key cost inputs and increased marketing expenses. In Europe, operating profit increased due to cost savings partially offset by inflation in key cost inputs and decreases in net selling prices. Operating profit in KCI decreased as higher sales volumes were more than offset by unfavorable currency effects, primarily in Venezuela, increases in marketing and general expenses and inflation in key cost inputs.
|
|
•
|
Consumer tissue segment operating profit decreased 10.3 percent. Increases in net selling prices, cost savings and lower general expenses were more than offset by inflation in key cost inputs, unfavorable currency effects, lower sales volumes and higher marketing expenses. Operating profit in North America decreased as increases in net selling prices and cost savings were more than offset by inflation in key cost inputs, lower sales volumes and higher marketing expenses. In Europe, operating profit increased as cost savings, higher net selling prices and lower general expenses were partially offset by inflation in key cost inputs. Operating profit in KCI decreased as higher net selling prices and improvements in product mix were more than offset by inflation in key cost inputs, unfavorable currency effects, primarily in Venezuela, and increased marketing, research and general expenses.
|
|
•
|
Operating profit for KCP & Other products increased 0.9 percent as higher net selling prices and cost savings were mostly offset by inflation in key cost inputs and unfavorable currency effects.
|
|
•
|
Operating profit for the health care segment decreased 28.7 percent. The benefit of higher sales volumes and cost savings were more than offset by higher selling and general expenses, including ongoing I-Flow litigation-related expenses, inflation in key cost inputs and lower net selling prices.
|
|
•
|
Interest expense increased in 2011 over 2010 due to a higher average level of debt. See Item 8, Note 8 to the Consolidated Financial Statements for detail on debt activity.
|
|
•
|
Our effective income tax rate was 30.2 percent for 2011 compared with 30.9 percent for 2010. The decrease was primarily due to the timing of tax initiatives.
|
|
•
|
Our share of net income of equity companies decreased by $20 million primarily due to lower earnings at Kimberly‑Clark de Mexico, S.A.B. de C.V. ("KCM"). KCM's net sales grew 4 percent due to a 2 percent benefit from the peso strengthening against the U.S. dollar, increased sales volumes of 1 percent, and a 1 percent impact from the combination of higher net selling prices and improvements in product mix. However, benefits from the increase in net sales were more than offset by inflation in key cost inputs, the negative effect of lower production volumes and increases in marketing expense.
|
|
•
|
The average number of common shares outstanding declined in 2011 as compared to 2010 due to share repurchases.
|
|
•
|
Interest expense decreased in 2010 as compared to 2009 due to a lower average level of debt and lower average interest rates.
|
|
•
|
Our effective income tax rate was 30.9 percent for 2010 compared with 29.0 percent for 2009. The increase was primarily due to nondeductible currency losses resulting from the adoption of highly inflationary accounting in Venezuela and changes in U.S. tax legislation, including a charge related to the Medicare Part D subsidy.
|
|
•
|
Our share of net income of equity companies increased by $17 million primarily due to higher earnings at KCM, whose U.S. dollar earnings benefited from the Mexican peso strengthening against the U.S. dollar by about 7 percent on average for the year, increases in sales volumes and net selling prices of 3 percent each, and cost savings. These benefits were partially offset by inflation in key cost inputs, primarily pulp.
|
|
•
|
The average number of common shares outstanding declined in 2010 as compared to 2009 due to share repurchases throughout 2010 under our share repurchase program.
|
|
|
Total
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017+
|
||||||||||||||
|
|
(Millions of dollars)
|
||||||||||||||||||||||||||
|
Long-term debt
|
$
|
6,045
|
|
|
$
|
619
|
|
|
$
|
592
|
|
|
$
|
524
|
|
|
$
|
344
|
|
|
$
|
51
|
|
|
$
|
3,915
|
|
|
Interest payments on long-term debt
|
3,406
|
|
|
311
|
|
|
280
|
|
|
249
|
|
|
236
|
|
|
221
|
|
|
2,109
|
|
|||||||
|
Returns on redeemable preferred securities
|
81
|
|
|
27
|
|
|
27
|
|
|
27
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
|
Operating leases
|
682
|
|
|
167
|
|
|
136
|
|
|
114
|
|
|
83
|
|
|
54
|
|
|
128
|
|
|||||||
|
Unconditional purchase obligations
|
1,001
|
|
|
709
|
|
|
154
|
|
|
44
|
|
|
17
|
|
|
18
|
|
|
59
|
|
|||||||
|
Open purchase orders
|
2,122
|
|
|
2,117
|
|
|
4
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
|
Total contractual obligations
|
$
|
13,337
|
|
|
$
|
3,950
|
|
|
$
|
1,193
|
|
|
$
|
959
|
|
|
$
|
680
|
|
|
$
|
344
|
|
|
$
|
6,211
|
|
|
•
|
Projected interest payments for variable-rate debt were calculated based on the outstanding principal amounts and prevailing market rates as of
December 31, 2011
.
|
|
•
|
Returns on redeemable preferred securities reflect required return payments through the next potential redemption date.
|
|
•
|
The unconditional purchase obligations are for the purchase of raw materials, primarily pulp, and utilities. Although we are primarily liable for payments on the above operating leases and unconditional purchase obligations, based on historic operating performance and forecasted future cash flows, we believe exposure to losses, if any, under these arrangements is not material.
|
|
•
|
The open purchase orders displayed in the table represent amounts for goods and services we have negotiated for delivery.
|
|
•
|
We will fund our defined benefit pension plans to meet or exceed statutory requirements and currently expect to contribute approximately
$50 million
to
$100 million
to these plans in
2012
.
|
|
•
|
Other postretirement benefit payments are estimated using actuarial assumptions, including expected future service, to project the future obligations. Based upon those projections, we anticipate making annual payments for these obligations of
$60 million
in
2012
to more than
$64 million
by
2021
.
|
|
•
|
Accrued income tax liabilities for uncertain tax positions, deferred taxes and noncontrolling interests.
|
|
•
|
In the event the holder of the redeemable preferred securities elects to redeem them at the next redemption election date, we would be required to repay approximately $500 million in
December 2014
.
|
|
•
|
During
2011
, our capital spending was
$968 million
. We expect capital spending to be $1.0 to $1.1 billion in 2012.
|
|
•
|
On July 7, 2011, we collected $220 million in cash related to a note receivable on its maturity date. See Item 8, Note 6 to the Consolidated Financial Statements for additional information.
|
|
•
|
At
December 31, 2011
and
2010
, total debt and redeemable securities was
$6.7 billion
and
$6.5 billion
, respectively.
|
|
•
|
We repurchase shares of Kimberly-Clark common stock from time to time pursuant to publicly announced share repurchase programs. During
2011
, we repurchased
$1.24 billion
of our common stock through a broker in the open market. In
2012
, we plan to repurchase
$900 million
to
$1.1 billion
of shares through open market purchases, subject to market conditions.
|
|
•
|
In February 2011, we issued
$250 million
of
3.875%
notes due
March 1, 2021
and
$450 million
of
5.3%
notes due
March 1, 2041
. Proceeds from the offering were used for general corporate purposes, including repurchasing shares of Kimberly-Clark common stock pursuant to publicly announced share repurchase programs.
|
|
•
|
On February 9, 2012, we issued $300 million of 2.4% notes due March 1, 2022. Proceeds from the offering were used for general corporate purposes, including to repay a portion of our $400 million aggregate principal amount of 5.625% notes that were due February 15, 2012.
|
|
•
|
In December 2011, we paid approximately $500 million to redeem a portion of the preferred securities of a consolidated financing subsidiary. See Item 8, Note 9 to the Consolidated Financial Statements for additional information.
|
|
•
|
In October 2011, we renegotiated our
$1.33 billion
unused revolving credit facility, resulting in (1) a five year facility of $1.5 billion scheduled to expire in October 2016, (2) an additional $500 million facility scheduled to expire in October 2012, and (3) an option to increase either (but not both) the $1.5 billion facility or the $500 million facility by an additional $500 million. This facility supports our commercial paper program and would provide liquidity in the event our access to the commercial paper markets is unavailable for any reason. We did not borrow any amounts under the revolving credit facility in 2011.
|
|
•
|
Our short-term debt as of
December 31, 2011
was
$87 million
(included in Debt payable within one year on the Consolidated Balance Sheet) and consisted of short-term debt issued by non-U.S. subsidiaries. The average month-end balance of short-term debt for the fourth quarter of
2011
was $91 million, and for the twelve months ended
December 31, 2011
was $214 million. These short-term borrowings, which included this short-term debt as well as commercial paper that we issued from time to time, provide supplemental funding for supporting our operations. The level of short-term debt generally fluctuates depending upon the amount of operating cash flows and the timing of customer receipts and payments for items such as dividends and income taxes.
|
|
•
|
During the second quarter of 2010, the Venezuelan government enacted reforms to its currency exchange regulations that limited U.S. dollar availability to pay for the historical levels of U.S. dollar-denominated imports to support operations of our Venezuelan subsidiary ("K-C Venezuela"). At
December 31, 2011
, our net investment in K‑C Venezuela was approximately
$250 million
, valued at
5.4
bolivars per U.S. dollar. See Item 8, Note 3 to the Consolidated Financial Statements for additional information.
|
|
ITEM 8.
|
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
|
|
Year Ended December 31
|
||||||||||
|
|
2011
|
|
2010
|
|
2009
|
||||||
|
|
(Millions of dollars, except per share amounts)
|
||||||||||
|
Net Sales
|
$
|
20,846
|
|
|
$
|
19,746
|
|
|
$
|
19,115
|
|
|
Cost of products sold
|
14,694
|
|
|
13,196
|
|
|
12,695
|
|
|||
|
Gross Profit
|
6,152
|
|
|
6,550
|
|
|
6,420
|
|
|||
|
Marketing, research and general expenses
|
3,761
|
|
|
3,673
|
|
|
3,498
|
|
|||
|
Other (income) and expense, net
|
(51
|
)
|
|
104
|
|
|
97
|
|
|||
|
Operating Profit
|
2,442
|
|
|
2,773
|
|
|
2,825
|
|
|||
|
Interest income
|
18
|
|
|
20
|
|
|
26
|
|
|||
|
Interest expense
|
(277
|
)
|
|
(243
|
)
|
|
(275
|
)
|
|||
|
Income Before Income Taxes and Equity Interests
|
2,183
|
|
|
2,550
|
|
|
2,576
|
|
|||
|
Provision for income taxes
|
(660
|
)
|
|
(788
|
)
|
|
(746
|
)
|
|||
|
Income Before Equity Interests
|
1,523
|
|
|
1,762
|
|
|
1,830
|
|
|||
|
Share of net income of equity companies
|
161
|
|
|
181
|
|
|
164
|
|
|||
|
Net Income
|
1,684
|
|
|
1,943
|
|
|
1,994
|
|
|||
|
Net income attributable to noncontrolling interests
|
(93
|
)
|
|
(100
|
)
|
|
(110
|
)
|
|||
|
Net Income Attributable to Kimberly-Clark Corporation
|
$
|
1,591
|
|
|
$
|
1,843
|
|
|
$
|
1,884
|
|
|
|
|
|
|
|
|
||||||
|
Per Share Basis
|
|
|
|
|
|
||||||
|
Basic
|
$
|
4.02
|
|
|
$
|
4.47
|
|
|
$
|
4.53
|
|
|
Diluted
|
$
|
3.99
|
|
|
$
|
4.45
|
|
|
$
|
4.52
|
|
|
|
Year Ended December 31
|
||||||||||
|
|
2011
|
|
2010
|
|
2009
|
||||||
|
|
(Millions of dollars)
|
||||||||||
|
Net Income
|
$
|
1,684
|
|
|
$
|
1,943
|
|
|
$
|
1,994
|
|
|
Other Comprehensive Income, Net of Tax:
|
|
|
|
|
|
||||||
|
Unrealized currency translation adjustments
|
(249
|
)
|
|
334
|
|
|
625
|
|
|||
|
Employee postretirement benefits
|
(134
|
)
|
|
55
|
|
|
(34
|
)
|
|||
|
Other
|
(30
|
)
|
|
(16
|
)
|
|
3
|
|
|||
|
Total Other Comprehensive Income, Net of Tax
|
(413
|
)
|
|
373
|
|
|
594
|
|
|||
|
Comprehensive Income
|
1,271
|
|
|
2,316
|
|
|
2,588
|
|
|||
|
Comprehensive income attributable to noncontrolling interests
|
(80
|
)
|
|
(106
|
)
|
|
(114
|
)
|
|||
|
Comprehensive Income Attributable to Kimberly-Clark Corporation
|
$
|
1,191
|
|
|
$
|
2,210
|
|
|
$
|
2,474
|
|
|
|
December 31
|
||||||
|
|
2011
|
|
2010
|
||||
|
|
(Millions of dollars)
|
||||||
|
ASSETS
|
|
|
|
||||
|
Current Assets
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
764
|
|
|
$
|
876
|
|
|
Accounts receivable, net
|
2,602
|
|
|
2,472
|
|
||
|
Note receivable
|
—
|
|
|
218
|
|
||
|
Inventories
|
2,356
|
|
|
2,373
|
|
||
|
Other current assets
|
561
|
|
|
389
|
|
||
|
Total Current Assets
|
6,283
|
|
|
6,328
|
|
||
|
Property, Plant and Equipment, net
|
8,049
|
|
|
8,356
|
|
||
|
Investments in Equity Companies
|
338
|
|
|
374
|
|
||
|
Goodwill
|
3,340
|
|
|
3,403
|
|
||
|
Other Intangible Assets
|
265
|
|
|
287
|
|
||
|
Long-Term Note Receivable
|
394
|
|
|
393
|
|
||
|
Other Assets
|
704
|
|
|
723
|
|
||
|
|
$
|
19,373
|
|
|
$
|
19,864
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
||||
|
Current Liabilities
|
|
|
|
||||
|
Debt payable within one year
|
$
|
706
|
|
|
$
|
344
|
|
|
Redeemable preferred securities of subsidiary
|
—
|
|
|
506
|
|
||
|
Trade accounts payable
|
2,388
|
|
|
2,206
|
|
||
|
Accrued expenses
|
2,026
|
|
|
2,013
|
|
||
|
Dividends payable
|
277
|
|
|
269
|
|
||
|
Total Current Liabilities
|
5,397
|
|
|
5,338
|
|
||
|
Long-Term Debt
|
5,426
|
|
|
5,120
|
|
||
|
Noncurrent Employee Benefits
|
1,460
|
|
|
1,810
|
|
||
|
|
|
|
|
||||
|
Other Liabilities
|
1,014
|
|
|
853
|
|
||
|
Redeemable Preferred and Common Securities of Subsidiaries
|
547
|
|
|
541
|
|
||
|
Stockholders’ Equity
|
|
|
|
||||
|
Kimberly-Clark Corporation Stockholders’ Equity:
|
|
|
|
||||
|
Preferred stock—no par value-authorized 20.0 million shares, none issued
|
—
|
|
|
—
|
|
||
|
Common stock—$1.25 par value—authorized 1.2 billion shares;
issued 428.6 and 478.6 million shares at December 31, 2011 and 2010 |
536
|
|
|
598
|
|
||
|
Additional paid-in capital
|
440
|
|
|
425
|
|
||
|
Common stock held in treasury, at cost—32.9 million and 71.7 million
shares at December 31, 2011 and 2010 |
(2,105
|
)
|
|
(4,726
|
)
|
||
|
Accumulated other comprehensive income (loss)
|
(1,866
|
)
|
|
(1,466
|
)
|
||
|
Retained earnings
|
8,244
|
|
|
11,086
|
|
||
|
Total Kimberly-Clark Corporation Stockholders’ Equity
|
5,249
|
|
|
5,917
|
|
||
|
Noncontrolling interests
|
280
|
|
|
285
|
|
||
|
Total Stockholders’ Equity
|
5,529
|
|
|
6,202
|
|
||
|
|
$
|
19,373
|
|
|
$
|
19,864
|
|
|
|
Common Stock
Issued
|
|
Additional
Paid-in
Capital
|
|
Treasury Stock
|
|
Retained
Earnings
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Noncontrolling
Interests
|
||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|||||||||||||||||||||
|
|
(Dollars in millions, shares in thousands)
|
||||||||||||||||||||||||||||
|
Balance at December 31, 2008
|
478,597
|
|
|
$
|
598
|
|
|
$
|
486
|
|
|
65,038
|
|
|
$
|
(4,285
|
)
|
|
$
|
9,465
|
|
|
$
|
(2,386
|
)
|
|
$
|
383
|
|
|
Net income in stockholders’ equity
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,884
|
|
|
—
|
|
|
54
|
|
||||||
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
Unrealized translation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
619
|
|
|
6
|
|
||||||
|
Employee postretirement
benefits, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(32
|
)
|
|
(2
|
)
|
||||||
|
Other
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3
|
|
|
—
|
|
||||||
|
Stock-based awards exercised or vested
|
—
|
|
|
—
|
|
|
(47
|
)
|
|
(3,519
|
)
|
|
204
|
|
|
(7
|
)
|
|
—
|
|
|
—
|
|
||||||
|
Income tax benefits on stock- based compensation
|
—
|
|
|
—
|
|
|
7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Shares repurchased
|
—
|
|
|
—
|
|
|
—
|
|
|
130
|
|
|
(7
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Recognition of stock-based compensation
|
—
|
|
|
—
|
|
|
86
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Dividends declared
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(996
|
)
|
|
—
|
|
|
(45
|
)
|
||||||
|
Additional investment in subsidiary and other
|
—
|
|
|
—
|
|
|
(133
|
)
|
|
—
|
|
|
1
|
|
|
(17
|
)
|
|
(37
|
)
|
|
(112
|
)
|
||||||
|
Balance at December 31, 2009
|
478,597
|
|
|
598
|
|
|
399
|
|
|
61,649
|
|
|
(4,087
|
)
|
|
10,329
|
|
|
(1,833
|
)
|
|
284
|
|
||||||
|
Net income in stockholders’ equity
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,843
|
|
|
—
|
|
|
44
|
|
||||||
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
Unrealized translation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
326
|
|
|
7
|
|
||||||
|
Employee postretirement benefits, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
57
|
|
|
(2
|
)
|
||||||
|
Other
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(16
|
)
|
|
—
|
|
||||||
|
Stock-based awards exercised or vested
|
—
|
|
|
—
|
|
|
(37
|
)
|
|
(2,862
|
)
|
|
170
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Income tax benefits on stock- based compensation
|
—
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Shares repurchased
|
—
|
|
|
—
|
|
|
—
|
|
|
12,954
|
|
|
(809
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Recognition of stock-based compensation
|
—
|
|
|
—
|
|
|
52
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Dividends declared
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,085
|
)
|
|
—
|
|
|
(47
|
)
|
||||||
|
Other
|
—
|
|
|
—
|
|
|
9
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
||||||
|
Balance at December 31, 2010
|
478,597
|
|
|
598
|
|
|
425
|
|
|
71,741
|
|
|
(4,726
|
)
|
|
11,086
|
|
|
(1,466
|
)
|
|
285
|
|
||||||
|
Net income in stockholders’ equity
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,591
|
|
|
—
|
|
|
39
|
|
||||||
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
Unrealized translation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(236
|
)
|
|
(13
|
)
|
||||||
|
Employee postretirement benefits, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(133
|
)
|
|
(1
|
)
|
||||||
|
Other
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(31
|
)
|
|
1
|
|
||||||
|
Stock-based awards exercised or vested
|
—
|
|
|
—
|
|
|
(47
|
)
|
|
(7,924
|
)
|
|
490
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Income tax benefits on stock- based compensation
|
—
|
|
|
—
|
|
|
10
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Shares repurchased
|
—
|
|
|
—
|
|
|
—
|
|
|
19,120
|
|
|
(1,247
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Shares retired
|
(50,000
|
)
|
|
(62
|
)
|
|
—
|
|
|
(50,000
|
)
|
|
3,378
|
|
|
(3,316
|
)
|
|
—
|
|
|
—
|
|
||||||
|
Recognition of stock-based compensation
|
—
|
|
|
—
|
|
|
48
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Dividends declared
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,107
|
)
|
|
—
|
|
|
(29
|
)
|
||||||
|
Other
|
—
|
|
|
—
|
|
|
4
|
|
|
—
|
|
|
—
|
|
|
(10
|
)
|
|
—
|
|
|
(2
|
)
|
||||||
|
Balance at December 31, 2011
|
428,597
|
|
|
$
|
536
|
|
|
$
|
440
|
|
|
32,937
|
|
|
$
|
(2,105
|
)
|
|
$
|
8,244
|
|
|
$
|
(1,866
|
)
|
|
$
|
280
|
|
|
|
Year Ended December 31
|
||||||||||
|
|
2011
|
|
2010
|
|
2009
|
||||||
|
|
(Millions of dollars)
|
||||||||||
|
Operating Activities
|
|
|
|
|
|
||||||
|
Net Income
|
$
|
1,684
|
|
|
$
|
1,943
|
|
|
$
|
1,994
|
|
|
Depreciation and amortization
|
1,091
|
|
|
813
|
|
|
783
|
|
|||
|
Asset Impairments
|
58
|
|
|
—
|
|
|
—
|
|
|||
|
Stock-based compensation
|
48
|
|
|
52
|
|
|
86
|
|
|||
|
Deferred income taxes
|
274
|
|
|
(12
|
)
|
|
141
|
|
|||
|
Net (gains) losses on asset dispositions
|
(6
|
)
|
|
26
|
|
|
36
|
|
|||
|
Equity companies’ earnings in excess of dividends paid
|
(23
|
)
|
|
(48
|
)
|
|
(53
|
)
|
|||
|
(Increase) decrease in operating working capital
|
(262
|
)
|
|
24
|
|
|
1,105
|
|
|||
|
Postretirement benefits
|
(574
|
)
|
|
(125
|
)
|
|
(609
|
)
|
|||